In the high-stakes world of pharmaceuticals, the path from innovation to patient access is often shrouded in complexity—and controversy. A recent investigation by Drug Patent Watch sheds startling light on the murky financial flows that underpin drug a…

Why the Orange Book’s Expiration Dates Don’t Match Real-World Generic Market Entry — And What You Should Use Instead
In the complex world of pharmaceuticals, timing is everything. For drug manufacturers, investors, and healthcare providers, understandi…

In the high-stakes world of pharmaceutical innovation, understanding the true timeline of a drug’s market exclusivity isn’t just a matter of academic interest — it’s a strategic imperative. Yet, many industry players, investors, and analysts often conf…

Are Pharma Vendors Losing Millions Because They’re Tracking Patent Expiry Wrong?
Imagine investing millions into a drug launch, only to find out you’ve missed the crucial patent expiry date — a mistake that could cost your company hundreds of millions …

The Patent Cliff Illusion: Why Generics Don’t Always Launch as Expected — And What It Means for the Future of Healthcare
Imagine a blockbuster drug that has dominated the market for years, promising patients relief and investors substantial returns. Wh…

In the high-stakes world of pharmaceuticals, the race to innovate is often overshadowed by the looming threat of generic entry—an event that can erode revenues overnight and threaten the very survival of blockbuster drugs. For pharmaceutical companies,…